Acorda Therapeutics (NASDAQ:ACOR) Now Covered by StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of Acorda Therapeutics (NASDAQ:ACOR) in a report issued on Sunday. The firm set a “buy” rating on the biopharmaceutical company’s stock.

Acorda Therapeutics Price Performance

Shares of NASDAQ:ACOR opened at $0.66 on Friday. Acorda Therapeutics has a 1 year low of $0.61 and a 1 year high of $24.20. The business has a fifty day simple moving average of $10.85 and a 200 day simple moving average of $12.06. The company has a current ratio of 0.33, a quick ratio of 0.26 and a debt-to-equity ratio of 3.07. The firm has a market cap of $819,640.00, a price-to-earnings ratio of 0.00 and a beta of 1.40.

About Acorda Therapeutics

Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen.